Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 93 clinical trials
Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial (DART)

patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or

covid-19
critical illness
nasopharyngeal swab
PCR test
FIO2
  • 69 views
  • 20 Jun, 2022
  • 1 location
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

acute pain
electrophoresis
chest syndrome
narcotics
acute chest syndrome
  • 0 views
  • 14 Apr, 2022
  • 1 location
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

This is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination

cell transplantation
lymphoma
classical hodgkin lymphoma
refractory hodgkin lymphoma
  • 1 views
  • 24 Feb, 2022
  • 1 location
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Main objective of this study is to describe and evaluate safety and efficacy of MBG453 (sabatolimab) in combination with FDA approved HMAs of investigator's choice (IV Decitabine or Azacitidine

EGFR
cell transplantation
azacitidine
decitabine
  • 0 views
  • 10 May, 2022
  • 17 locations
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating patients

cytarabine
enasidenib
cancer
IDH2
decitabine
  • 0 views
  • 12 Jul, 2021
  • 1 location
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

(cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows

  • 0 views
  • 15 Mar, 2022
  • 7 locations
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal

measurable disease
  • 0 views
  • 02 Feb, 2022
  • 2 locations
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

ejection fraction
colony stimulating factor
cytarabine
granulocyte colony stimulating factor
acute promyelocytic leukemia
  • 1 views
  • 05 Mar, 2022
  • 1 location
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles. If PR or CR

platelet count
lymphoma
pd-1 inhibitor
  • 0 views
  • 22 Dec, 2021
  • 1 location
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax (ENABLE)

Prospective, multi-center, intervention, open clinical trial for the treatment of AML secondary to MPN in patients unfit for intensive chemotherapy investigating a combination regimen including VEN and DEC.

venetoclax
decitabine
  • 0 views
  • 22 Mar, 2022